

### Author Response 3

Reviewer: 3

Comments to the Author

Thank you for the revision and changes - significantly better.

Please change the following paragraphs of introduction :

"No standard chemotherapeutic regimen for SCLC patients with IPF has been established. The right or wrong of the definitive radiotherapy to the lung has not been also established because the radiotherapy produces a radiation pneumonitis with high probability that can become fatal.

Therefore, the right or wrong of the definitive radiotherapy to the lung in patients with IPF has not been also established. In cases of SCLC with underlying ILD, the efficacy and safety of chemotherapy and chemoradiotherapy are largely unknown.

Because there is limited clinical information regarding SCLC patients with IPF is limited, we conducted this study investigated clinical features of SCLC patients with a larger scale than those of the prior investigations. Wwe retrospectively compared the efficacy of first-line therapy and factors related to survival in SCLC patients with IPF "

Into something like :

" As radiation can produce significant pneumonitis ( reference) the correct dose of radiotherapy ,no standard chemotherapeutic regimen for SCLC patients with IPF has been established ( reference).

In cases of SCLC with underlying ILD, the efficacy and safety of chemotherapy and chemoradiotherapy are largely unknown as well ( reference).

Because information regarding SCLC patients with IPF is limited, we conducted this larger scale study. We have retrospectively compared the efficacy of first-line SCLC therapy and factors related to survival in patients with IPF.

Response: Thank you very much for your careful reading our manuscript again and providing a concrete suggestion.

We revised this part into: "No standard chemotherapeutic regimen for SCLC patients with IPF has been established (reference). As radiation can produce significant pneumonitis, the correct dose of radiotherapy to the lung in patients with IPF has not been also established (reference). In cases of SCLC with underlying IPF, the efficacy and safety of chemotherapy and chemoradiotherapy are largely unknown as well (reference).

Because information regarding SCLC patients with IPF is limited, we conducted this larger scale study. We have retrospectively compared the efficacy of first-line SCLC therapy and factors related to survival in patients with IPF with those of patients without ILD."